Observational analysis found survival rates improved based on genomic risk factors in patients undergoing hematopoietic cell transplantation, highlighting the role of genetic findings.
Key Points
Survival rates significantly differ based on genomic risk factors, with rates at 94.8%, 84.8%, and 58.5% for 0, 1, and ≥2 factors respectively.
Comprehensive genomic evaluations revealed that 79.9% of participants had primary findings relevant to hemato-poietic cell transplantation indications.
Utilizing Kaplan-Meier survival analysis allowed for the comparison of survival rates based on genomic findings in the cohort.
Identification of relevant genomic data may enhance the personalized approach to hematopoietic cell transplantation in patients with immune disorders.